Nucana Plc shares surge 45% in premarket after receiving Nasdaq delisting notice and strong industry performance.
ByAinvest
Thursday, Jul 10, 2025 5:06 am ET1min read
NCNA--
Nucana Plc surged 45% in premarket trading, driven by a 0.59% overall increase in the European ADR market and a 19% rise in the stock price of UK and Irish healthcare companies. The company, a clinical-stage biopharmaceutical firm, focuses on developing new cancer drugs using ProTide technology to enhance the efficacy and safety of existing therapies. Additionally, NuCana received a delisting notice from Nasdaq due to its stock price falling below $0.10 for 10 consecutive days, but has announced plans to request a hearing to temporarily halt the delisting process.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet